Introduction
============

Lymphoblastic lymphoma (LBL) is an invasive neoplasm resembling acute lymphoblastic leukemia \[[@b1-crt-2019-542]\]. It is of precursor T-cell (T-LBL) or B-cell (B-LBL) lineage \[[@b2-crt-2019-542]\]. Despite the great histologic similarities between T-LBL and B-LBL, there are still some different clinical features between T-LBL and B-LBL. T-LBL is featured by mediastinal and lymph node invasion. Compared with T-LBL, B-LBL has yet to be extensively studied for B-LBL is a rare disease, accounting for 10%-20% of LBL patients. The clinical features of B-LBL have not been fully reported, especially in adult patients. Most studies on B-LBL are focused on pediatric patients \[[@b3-crt-2019-542]\]. Current treatment strategies of LBL are based on intensive multidrug ALL‐type chemotherapy. The conventional or intensive chemotherapy protocols for non-Hodgkin lymphoma (NHL) have produced relatively poor outcomes \[[@b4-crt-2019-542],[@b5-crt-2019-542]\], therefore were abandoned. Multiple studies have reported that improvements in long-term outcome were achieved with ALL-type protocols in LBL \[[@b6-crt-2019-542]-[@b8-crt-2019-542]\]. In 2010, the non-Hodgkin lymphoma Berlin--Frankfurt--Münster-95 (NHL-BFM-95) regimen was modified in our department and used to treat adult patients with LBL; in the meanwhile, a standard hyperfractionated cyclophosphamide, vincristine, adriamycin, dexamethasone/methotrexate, and cytarabine (HyperCVAD/MA) was also applied to adult patients with LBL. The purpose of the present study was to further analyze the clinical characteristics and prognostic factors in LBL and to evaluate two regimens (HyperCVAD and modified NHL-BFM-95) used to treat adult LBL.

Materials and Methods
=====================

1. Study group
--------------

This study included a total of 207 consecutive patients newly diagnosed with LBL at two hospitals in China (Sun Yat-sen University Cancer Center and The First Affiliated Hospital of Hainan Medical College) from January 2000 to August 2018. The inclusion criteria were as follows: (1) patients pathologically diagnosed with LBL based on the revised European--American lymphoma classification \[[@b3-crt-2019-542]\]; (2) patients over 18 years old; (3) patients at any stage with normal internal organ functions, unless directly altered by the disease. The exclusion criteria were as follows: (1) patients with Phpositive B-LBL was excluded from the study for the unique clinical characteristics and treatment strategies; (2) according to World Health Organization 2016 classification, patients who had more than 20% blasts in the bone marrow (BM) were defined as ALL and were excluded from this study; (3) patients with severe immunodeficiency or pre-existing diseases preventing che-motherapy. The clinical stage was assessed according to the Ann Arbor NHL system. Information was derived from pretreatment evaluations and re-evaluations. Eastern Cooperative Oncology Group (ECOG) score was used to evaluate the patients' performance status. Central nervous system (CNS) invasion was diagnosed by blast cells discovered in the cerebrospinal fluid or cerebral infiltration on imaging examination. BM invasion was defined as \> 5% blasts in the BM. According to international prognostic index (IPI), patients were classified into low-risk group (IPI \< 3) and high-risk group (IPI ≥ 3). Adolescent and young adult (AYA) is usually defined as individuals 15-39 years old. In this study, patients \< 40 years was considered a distinct age group.

2. Treatment
------------

The HyperCVAD/MA regimen in the present study was the standard regimen have been reported previously \[[@b6-crt-2019-542]\]. The regimen included eight cycles of induction-consolidation courses alternating HyperCVAD with high-dose methotrexate (HD-MTX) and cytarabine and a maintenance phase. Mediastinal irradiation was recommended for patients with mediastinal disease. Maintenance therapy lasted for 24 months. The details of induction/consolidation/maintenance phases were described in [S1 Table](#SD1-crt-2019-542){ref-type="supplementary-material"}.

The modified NHL-BFM-95 protocol was originated from NHL-BFM-95 regimen. The following differences were observed: (1) to avoid cardiotoxicity, pirarubicin replaced daunorubicin in induction protocol 1A and the reinduction protocol 2A; (2) due to the modification of polyethylene glycol (PEG), pegaspargase overcomes the immunogenicity and severe allergic reaction of asparaginase, and has a longer half-live; so, we substituted pegaspargase for L-asparaginase as the inductive drug in induction protocol IA and reinduction protocol IIA; (3) a routine intrathecal chemotherapy and additional four HD-MTX treatments during maintenance phase instead of intracranial prophylactic radiotherapy to prevent CNS invasion. (4) Citrovorum folinate was administered at a dose of 15 mg/m^2^ at 36, 42, 48, 54, 60, 66, and 72 hours after high-dose methotrexate.

Schemes of induction, M, reinduction, and maintenance treatment were described in [Table 1](#t1-crt-2019-542){ref-type="table"}. Treatment lasted for 30 months.

Rituximab was not used in the B-LBL cohort.

3. Response assessment
----------------------

The response was assessed after each chemotherapy session (e.g., induction I and II). After the chemotherapy was completed, the clinical response was assessed every 3 months for the first 2 years after treatment and afterward every half a year for the next 3 years. Complete remission (CR) was described as the normalization of any abnormal lymphadenopathy through physical and imaging examinations. For patients with initial BM invasion, CR was described as less than 5% of the blasts though BM aspiration. Minimal residual disease (MRD) was tested after consolidation regimen via multi-parametric flow cytometry with an eight-color panel, and the sensitivity was 0.01%. Partial remission was described as a 70% to 50% reduction in tumor size. Progression was descri-bed as an increase of \> 25% in residual tumor size.

4. Statistical analysis
-----------------------

Clinical features were compared using two-tailed chi-square tests, Fisher exact test, or Wilcoxon rank-sum test between two subtypes. Overall survival (OS) was estimated from diagnosis to death from any cause. Progression-free survival (PFS) was described as the time from diagnosis to the primary occurrence of progression or death from any cause. Patients who did not experience any of these events or lost to follow-up were censored. Estimates of PFS and OS distributions were calculated by the Kaplan-Meier method and compared by the log-rank test. Prognostic factors were primarily screened by univariate analysis and then evaluated by multivariate analysis. Due to limited cases, multivariate cox regression analysis was not performed to patients with B-LBL. Statistical analysis was performed with SPSS ver. 17.0 (SPSS Inc., Chicago, IL) and the figures were drawn with GraphPad Prism 7 (San Diego, CA).

5. Ethical statement
--------------------

All procedures performed in studies involving human participants were in accordance with the ethical standards of the ethics committee and the institutional review board of two hospitals (Sun Yat-sen University Cancer Center and The First Affiliated Hospital of Hainan Medical College) (GYX-2019-023) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Results
=======

1. Clinical manifestation
-------------------------

The clinical features of 207 LBL patients in two differently treated groups are recorded in [Table 2](#t2-crt-2019-542){ref-type="table"}. Sixty-five point seven percent of the patients were treated with modified NHL-BFM-95 and 34.3% were treated with HyperCVAD/MA. The median age was 28 years in patients treated with modified NHL-BFM-95 and 32 years in patients treated with HyperCVAD/MA (p=0.050). More patients were \< 40 years in the modified NHL-BFM-95 group than the HyperCVAD/MA group (80.1% vs. 64.8%, p=0.016). In this study, serum lactate dehydrogenase (LDH) level was defined elevated when it was \> 245 U/L. LDH was more frequently found to be elevated in patients treated with modified NHL-BFM-95 than those treated with HyperCVAD/MA (63.2% vs. 42.3%, p=0.004). Other clinical features including sex, immunophenotype, ECOG scores, stage, B symptom, mediastinal mass, BM invasion, CNS involvement, and IPI were similar between the two treatment groups.

2. Treatment outcomes and survival
----------------------------------

The median duration of OS for LBL patients was 54.0 months (95% confidence interval \[CI\], 31.5 to 76.5 months). The estimated 1-year, 3-year, 5-year and 7-year OS rates were 89.2%±2.2%, 52.2%±3.6%, 45.7%±3.8%, and 41.0%±4.1%, respectively. The median duration of PFS was 70.0 months (95% CI, 42.2 to 97.8 months). The estimated 1-year, 3-year, 5-year and 7-year PFS rates were 76.0%±3.0%, 46,3%±3,6%, 40.3%± 3.8%, and 33,2%±4.3%, respectively ([Fig. 1A](#f1-crt-2019-542){ref-type="fig"}and [B](#f1-crt-2019-542){ref-type="fig"}).

The treatment outcomes of two treatment groups were demonstrated in [Table 3](#t3-crt-2019-542){ref-type="table"}. There were no significant differences between two groups concerning CR after induction and MRD negative after consolidation therapy. However, there was a tendency of higher CR and MRD negative rates in modified NHL-BFM-95 group than in the HyperCVAD group (77.9% vs. 66.2%, 69.1% vs. 60.1%, respectively). 5-year OS and PFS were both significantly higher in patients treated with modified NHL-BFM-95 regimen (53.9% vs. 30.2%, 47.9% vs. 25.9%, respectively, p=0.005) ([Fig. 1C](#f1-crt-2019-542){ref-type="fig"} and [D](#f1-crt-2019-542){ref-type="fig"}).

[Table 4](#t4-crt-2019-542){ref-type="table"} demonstrated treatment response of two regimens in T-LBL and B-LBL patients. For patients with T-LBL, the CR and MRD negative rates between two treatment groups were significantly different (p=0.036 and p=0.043, respectively). Patients were more likely to achieve CR and MRD negative with modified NHL-BFM-95 regimen than Hyper-CVAD/MA (76.7% vs. 64.0%, 68.9% vs. 53.4%, respectively). In the meanwhile, for patients with B-LBL, the response between two treatment groups was not significantly different.

On the other hand, the impact of two regimens on survival was different between T-LBL and B-LBL. For patients with T-LBL, modified NHL-BFM-95 regimen produced a significant higher OS and PFS than those in HyperCVAD/MA group (p=0.006 and p=0.004, respectively) ([Fig. 2A](#f2-crt-2019-542){ref-type="fig"} and [B](#f2-crt-2019-542){ref-type="fig"}). In the meanwhile, for patients with B-LBL, there is no significant difference in OS and PFS between two regimens ([Fig. 2C](#f2-crt-2019-542){ref-type="fig"} and [D](#f2-crt-2019-542){ref-type="fig"}).

The outcomes of two regimens in different age group (patients \< 40 and ≥ 40 years) was analyzed ([Fig. 3](#f3-crt-2019-542){ref-type="fig"}). For patients \< 40 years, modified NHL-BFM-95 regimen produced a significantly higher OS and PFS than those in HyperCVAD/MA group (p=0.001) ([Fig. 3A](#f3-crt-2019-542){ref-type="fig"} and [B](#f3-crt-2019-542){ref-type="fig"}). In the meanwhile, for patients ≥ 40 years, there is no significant difference of OS and PFS between two regimens ([Fig. 3C](#f3-crt-2019-542){ref-type="fig"} and [D](#f3-crt-2019-542){ref-type="fig"}). In summary, modified NHL-BFM-95 regimen produced better outcomes than HyperCVAD/MA in younger population.

3. Univariate and multivariate analyses
---------------------------------------

The prognostic factors for patients with T-LBL are summarized in [Table 5](#t5-crt-2019-542){ref-type="table"}. In univariate analysis, HyperCVAD/MA, high ECOG scores, BM invasion, and high IPI were adverse factors for OS and PFS. In the multivariable analysis, Hyper-CVAD/MA, high ECOG scores and BM involvement were independent risk factors for OS and PFS. The prognostic factors for patients with B-LBL are summarized in [Table 6](#t6-crt-2019-542){ref-type="table"}. In univariate analysis, elevated LDH level and high IPI were adverse prognostic factors for OS and PFS. Other factors, including age, sex, ECOG grades, white blood cell count, clinical stage, B symptoms, BM involvement and treatment, did not affect the outcome significantly.

4. Toxicity
-----------

All the patients who received modified NHL-BFM-95 or HyperCVAD exhibited III/IV grade myelosuppression during remission induction. The myelosuppression included low WBC accounts of 0.05-0.7×10^9^/L, hemoglobin level of 23-70 g/L and platelet count of 1-20×10^9^/L. Fifty-eight patients developed serious infections and recovered after treatment stopped. No treatment-related mortality was observed in both treatment groups. Other side effects including allergic reaction, hypofibrinogenemia, pancreatitis, elevated liver enzymes and bilirubin, osteonecrosis, thrombosis, stroke-like event, and neuropathy were compared between two treatment groups in [Table 3](#t3-crt-2019-542){ref-type="table"}. No patients interrupted treatment for severe adverse events.

Discussion
==========

As previously reported, encouraging results were obtained with ALL‐type regimens in adult LBL patients. However, few studies directly compare the efficacies of two ALL‐type regimens. The present study demonstrated a modified NHL-BFM-95 regimen and compared with HyperCVAD in LBL patients. Our study found that the modified NHL-BFM-95 regimen produced superior outcomes than HyperCVAD in T-LBL patients, but not in B-LBL. Our study also analyzed the clinical features, outcome, and prognostic factors of 207 adult LBL patients diagnosed at two hospitals from 2000 to 2018.

The clinical characteristics of the LBL patients were analyzed in the present study. Most clinical characteristics were similar between the two treatment groups except for age and LDH level. Patients treated with modified NHL-BFM-95 regimen were more likely to be younger and with elevated LDH level. Age has not been identified as a significant prognostic factor in adult LBL in previous studies \[[@b7-crt-2019-542],[@b9-crt-2019-542]\]. In a study on adult T-LBL \[[@b8-crt-2019-542]\], elevated LDH level was the only significant risk factor for poor survival. In summary, the predominance of elevated LDH level in the modified NHL-BFM-95 group was an unfavorable factor for patient outcomes.

In this study, the 5-year OS rate and the PFS rate of LBL patients were 45.7% and 40.3%, respectively, and they were consistent with previous studies \[[@b8-crt-2019-542],[@b10-crt-2019-542]\]. [Table 3](#t3-crt-2019-542){ref-type="table"} showed that the 5-year OS and PFS rates of modified NHL-BFM-95 group were significantly higher than HyperCVAD/MA group, which was different with a previous report comparing an augmented BFM therapy with HyperCVAD in ALL patients \[[@b11-crt-2019-542]\]. This previous study reported that a 3-year OS of 74% in augmented BFM group versus 71% in HyperCVAD group in AYAs with ALL. The augmented BFM group was not associated with significant improvements in OS compared with HyperCAVD. The different study group and treatment regimen may contribute to different results.

Comparison of characteristics of modified NHL-BFM-95, HyperCVAD with previously published AYA protocol CALGB 10403 \[[@b12-crt-2019-542]\] was demonstrated in [Table 7](#t7-crt-2019-542){ref-type="table"}. The present study enrolled patients with older age. All patients were under 40 years in the CALGB 10403 study and 19.9% in the modified NHL-BFM-95 group were 40 or older. Patients in our study also had worse performance status. Thirty-one point three percent of the population in the CALGB 10403 study were Ph-positive; while, Ph-positive patients were excluded from our study. Besides, most of our enrollment were of T-cell lineage, but the situation was reversed in the CALGB 10403 study. The treatment outcomes of modified NHL-BFM-95 group, including CR rate, OS and PFS, were inferior compared with the CALGB 10403 study. The unfavorable results in our study could due to the generally worse characteristics of older age and poorer performance status of patients.

Seventy-two point six percent T-LBL patients and 78.0% B-LBL patients reached CR at the end of induction I; 63.4 % T-LBL patients and 58.7% B-LBL patients reached MRD negative after consolidation regimen. The results were consistent with previous studies \[[@b5-crt-2019-542],[@b13-crt-2019-542]\]. In our study, for T-LBL patients, they were more likely to achieve CR and MRD negative when treated with the modified NHL-BFM-95 regimen, suggesting that the modified NHL-BFM-95 regimen could be a favorable option for T-LBL. In the meanwhile, for patients with B-LBL, modified NHL-BFM-95 and hyper CVAD/MA produced similar outcomes. Different mechanisms of B-LBL may explain the results.

AYA patients (15-39 years) with cancer is considered as a unique population with different treatment response and clinical outcomes. In the present study, modified NHL-BFM-95 regimen produced better outcomes than HyperCVAD/MA in patients \< 40 years. In the meanwhile, in the older age group, there was no significant difference between the outcomes of two regimens. The result was consistent with previous studies on ALL. Multiple studies have suggested that "pediatric" approaches (e.g., NHL-BFM regimen) produced better outcomes than "adult" approaches (e.g., hyper‐CVAD regimen) in patients with ALL \[[@b14-crt-2019-542]-[@b19-crt-2019-542]\]. This present study added new evidence supporting modified NHL-BFM-95 in young adult LBL patients.

Risk factors have been discussed in many studies. Unlike the prognostic factors of ALL, strong and reliable prognostic factors of LBL have yet to be established. Most studies on adult LBL have identified age \> 40 years, male sex, increased LDH, BM or CNS infiltration, and high IPI as risk factors. However, these findings were inconsistent among studies \[[@b9-crt-2019-542],[@b20-crt-2019-542]\]. In contrast to other reports \[[@b8-crt-2019-542],[@b11-crt-2019-542]\], our study found that sex did not influence T-LBL or B-LBL outcomes. In the present study, for patients with T-LBL, high ECOG scores, BM invasion, and HyperCVAD/MA affected OS and PFS. High ECOG scores contributed to a poor outcome, suggesting that the use of numerous supportive treatments could improve the prognosis of T-LBL. BM invasion negatively affected the outcome. Thus, more effective and novel therapy are needed, especially for patients with BM invasion. For patients with B-LBL, through univariate analysis, elevated LDH level and high IPI significantly influenced the OS and PFS rates. Prognostic factors were similar but not entirely identical between B-LBL and T-LBL, which could be explained by smaller series of B-LBL group. The treatment was an independent prognostic factor in T-LBL, not in B-LBL, suggesting that the modified NHL-BFM-95 regimen was a preferred treatment than HyperCVAD/MA for patients with T-LBL.

In the present study, we evaluated the efficacy of a modified regimen evolved from NHL-BFM-95 regimen. In induction therapy, we replaced daunorubicin by pirarubicin at same dose to avoid cardiac toxicity. Pegaspargase has lower immunogenicity and longer half-life and been a standard treatment in ALL therapy for children and adults \[[@b21-crt-2019-542]-[@b23-crt-2019-542]\]. Thus, in this study, L-asparaginase was substituted by pegaspargase as inductive drug for more convenient dosage regimen and potentially reduced immunogenicity. The common adverse reactions of pegaspargase, including hypersensitivity reactions, pancreatitis and thrombotic complications \[[@b22-crt-2019-542]\], were closely monitored. The adverse reactions related to pegaspargase observed in the present study were consistent with previously reported studies with adult ALL \[[@b24-crt-2019-542],[@b25-crt-2019-542]\], indicating that the dosage of pegaspargase in our study was well-tolerated. CNS invasion at diagnosis is commonly observed in 3%-15% LBL patients \[[@b26-crt-2019-542],[@b27-crt-2019-542]\], and even more frequent in relapsed patients, particularly without adequate CNS prophylaxis. In our study, five patients presented CNS invasion at diagnosis, and no patient experienced relapse with CNS involvement after treatment. The results suggested that intrathecal chemotherapy and additional four HD-MTX treatments in the modified NHL-BFM-95 regimen were adequate CNS protection.

This study reported one of the largest series of research on adult Chinese patients with LBL. The clinical characteristics and prognostic factors were analyzed. Our study showed that the modified NHL-BFM-95 regimen was a preferred treatment than HyperCVAD/MA for patients with T-LBL or young adult patients (\< 40 years). Still, the survival rates of LBL were poor. Hence, novel treatments were demanded. Future randomized trials are warranted to evaluated modified NHL-BFM-95 regimen in larger population. We hope that our study can provide more insights into therapeutic strategies.
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Protocols of hyperCVAD/MA regimen

![(A, B) Kaplan-Meier curves for overall survival (OS) (A) and progression-free survival (PFS) (B) among 207 patients with lymphoblastic lymphoma (LBL). (C, D) Kaplan-Meier curves comparing OS (C) and PFS (D) between patients who received modified NHL-BFM-95 (non-Hodgkin lymphoma Berlin--Frankfurt--Münster-95) and HyperCVAD/MA (hyperfractionated cyclophosphamide, vincristine, adriamycin, dexamethasone/methotrexate, and cytarabine).](crt-2019-542f1){#f1-crt-2019-542}

![Kaplan-Meier curves comparing overall survival (OS) and progression-free survival (PFS) between patients receiving modified NHL-BFM-95 (non-Hodgkin lymphoma Berlin--Frankfurt--Münster-95) regimen and those receiving HyperCVAD/MA (hyperfractionated cyclophosphamide, vincristine, adriamycin, dexamethasone/methotrexate, and cytarabine) according to different cell lineages. (A) OS of patients with T-LBL (p=0.006). (B) PFS of patients with T-LBL (p=0.004). (C) OS of patients with B-LBL (p=0.329). (D) PFS of patients with B-LBL (p=0.510).](crt-2019-542f2){#f2-crt-2019-542}

![Kaplan-Meier curves comparing overall survival (OS) and progression-free survival (PFS) between patients receiving modified NHL-BFM-95 (non-Hodgkin lymphoma Berlin--Frankfurt--Münster-95) regimen and those receiving HyperCVAD/MA (hyperfractionated cyclophosphamide, vincristine, adriamycin, dexamethasone/methotrexate, and cytarabine) according to age. (A) OS of adolescent and young adult population (p=0.001). (B) PFS of adolescent and young adult population (p=0.001). (C) OS of patients \> 40 years (p=0.899). (D) PFS of patients \> 40 years (p=0.894).](crt-2019-542f3){#f3-crt-2019-542}

###### 

Protocols of modified NHL-BFM-95 regimen

  Drug                                                              Dose                     Days of administration
  ----------------------------------------------------------------- ------------------------ --------------------------------
  **Induction protocol IA**                                                                  
   Prednisone (PO)                                                  60 mg/m^2^ per day       1-28, then taper over 3×3 days
   Vincristine (IV)                                                 1.5 mg/m^2^ (max 2 mg)   8, 15, 22, 29
   Pirarubicin (IV)                                                 30 mg/m^2^               8, 15, 22, 29
   Pegaspargase (IM)                                                2,500 IU/m^2^            1,529
   IT chemotherapy^[a)](#tfn1-crt-2019-542){ref-type="table-fn"}^                            1,12,33
  **Induction protocol IB**                                                                  
   Cyclophosphamide (IV)                                            1,000 mg/m^2^ per dose   3,664
   Cytarabine (IV)                                                  75 mg/m^2^               38-41, 45-48, 52-55, 59-62
   6-Mercaptopurine (PO)                                            60 mg/m^2^               36-63
   IT chemotherapy^[a)](#tfn1-crt-2019-542){ref-type="table-fn"}^                            4,559
  **Protocol M**                                                                             
   6-Mercaptopurine (oral)                                          25 mg/m^2^ per day       1-56
   Methotrexate^[b)](#tfn2-crt-2019-542){ref-type="table-fn"}^      5 g/m^2^                 8, 22, 36, 50
   Methotrexate (IT)                                                                         8, 22, 36, 50
  **Reinduction protocol IIA**                                                               
   Dexamethasone (PO)                                               60 mg/m^2^ per day       1-21, then taper over 3×3 days
   Vincristine (IV)                                                 1.5 mg/m^2^ (max 2 mg)   8, 15, 22, 29
   Pirarubicin (IV)                                                 30 mg/m^2^               8, 15, 22, 29
   Pegaspargase (IM)                                                2,500 IU/m^2^            8
  **Reinduction protocol IIB**                                                               
   Cyclophosphamide (IV)                                            1,000 mg/m^2^ per dose   36
   Cytarabine (IV)                                                  75 mg/m^2^ per dose      38-41, 45-48
   6-Thioguanine (PO)                                               60 mg/m^2^ per day       36-49
   IT chemotherapy^[a)](#tfn1-crt-2019-542){ref-type="table-fn"}^                            45, 59
  **Maintenance therapy**                                                                    
   Methotrexate (PO)                                                20 mg/m^2^ per dose      Once a week
   6-Mercaptopurine (PO)                                            50 mg/m^2^ per day       Daily
   Methotrexate^[b)](#tfn2-crt-2019-542){ref-type="table-fn"}^      5 g/m^2^                 4 doses, 3-mo intervals

NHL-BFM-95, non-Hodgkin lymphoma Berlin--Frankfurt--Münster-95; PO, oral; IV, intravenously; IM, intramuscularly; IT, intrathecal.

Intrathecal (IT) drugs: methotrexate (15 mg/m^2^), cytarabine (40 mg/m^2^), and dexamethasone (4 mg),

Onetenth of the methotrexate was administered within the first 0.5 hours, and the rest was given through IV drip over 23.5 hours.

###### 

Baseline characteristics of patients in two differently treated group

  Parameter                  Modified NHL-BFM-95   HyperCVAD/MA   p-value
  -------------------------- --------------------- -------------- ---------
  **Total**                  136                   71             
  **Age (yr)**                                                    
   \< 40                     109 (80.1)            46 (64.8)      0.016
   ≥ 40                      27 (19.9)             25 (35.2)      
  **Sex**                                                         
   Male                      87 (64.0)             47 (66.2)      0.750
   Female                    49 (36.0)             24 (33.8)      
  **Immunophenotype**                                             
   B-LBL                     29 (21.3)             21 (29.6)      0.188
   T-LBL                     107 (78.7)            50 (70.4)      
  **ECOG**                                                        
   ≤ 2                       106 (77.9)            57 (80.3)      0.982
   \> 2                      30 (22.1)             14 (19.7)      
  **Stage**                                                       
   Ⅰ/Ⅱ                       22 (16.2)             17 (23.9)      0.175
   Ⅲ/Ⅳ                       114 (83.8)            54 (76.1)      
  **B symptom**                                                   
   Yes                       87 (64.0)             42 (59.2)      0.497
   No                        49 (36.0)             29 (40.8)      
  **Mediastinal mass**                                            
   Yes                       46 (33.8)             32 (45.1)      0.113
   No                        90 (66.2)             39 (54.9)      
  **LDH elevated**                                                
   Yes                       86 (63.2)             30 (42.3)      0.004
   No                        50 (36.8)             41 (57.7)      
  **Bone marrow invasion**                                        
   Yes                       69 (50.7)             40 (56.3)      0.443
   No                        67 (49.3)             31 (43.7)      
  **CNS involvement**                                             
   Yes                       3 (2.2)               2 (2.8)        \> 0.99
   No                        133 (97.8)            69 (97.2)      
  **IPI**                                                         
   Low risk                  107 (78.7)            48 (67.6)      0.081
   High risk                 29 (21.3)             23 (32.4)      

Values are presented as number (%). NHL-BFM-95, non-Hodgkin lymphoma Berlin--Frankfurt--Münster-95; HyperCVAD/MA, hyperfractionated cyclophosphamide, vincristine, adriamycin, dexamethasone/methotrexate, and cytarabine; ECOG, Eastern Cooperative Oncology Group; T-LBL, T-lymphoblastic lymphoma; B-LBL, B lymphoblastic lymphoma; LDH, lactate dehydrogenase; CNS, central nervous system; IPI, international prognostic index.

###### 

Treatment outcomes of patients in different treatment groups

  Parameter                              Modified NHL-BFM-95   HyperCVAD/MA   p-value
  -------------------------------------- --------------------- -------------- ---------
  **Total**                              136                   71             
  **CR after induction**                 106 (77.9)            47 (66.2)      0.052
  **MRD negative after consolidation**   94 (69.1)             43 (60.1)      0.088
  **5-Year OS**                          53.9                  30.2           0.005
  **5-Year PFS**                         47.9                  25.9           0.005
  **Treatment-related mortality**        0                     0              
  **Toxicity**                                                                
   Allergic reaction                     8 (5.9)               6 (8.5)        
   Hypofibrinogenemia                    33 (24.3)             13 (18.3)      
   Pancreatitis                          8 (5.9)               3 (4.2)        
   Elevated liver enzymes                47 (34.6)             33 (46.5)      
   Elevated bilirubin                    27 (19.9)             16 (22.5)      
   Osteonecrosis                         9 (6.6)               4 (5.6)        
   Thrombosis                            19 (14.0)             12 (16.9)      
   Stroke-like event                     4 (2.9)               2 (2.8)        
   Neuropathy                            10 (7.4)              9 (12.7)       

Values are presented as number (%). NHL-BFM-95, non-Hodgkin lymphoma Berlin--Frankfurt--Münster-95; Hyper-CVAD/MA, hyperfractionated cyclophosphamide, vincristine, adriamycin, dexamethasone/methotrexate, and cytarabine; CR, complete remission; MRD, minimal residual disease; OS, overall survival; PFS, progression-free survival.

###### 

Response to treatment in T-LBL and B-LBL patients according to treatment

                                T-LBL   B-LBL                                        
  ----------------------------- ------- ------- ------ ------- ------ ------- ------ -------
  Modified NHL-BFM-95 (n=136)   76.6    0.036   68.9   0.043   82.8   0.741   62.3   0.652
  HyperCVAD/MA (n=71)           64.0            53.4           71.4           51.4   
  Total (n=207)                 72.6            63.4           78.0           58.7   

T-LBL, T-lymphoblastic lymphoma; B-LBL, B lymphoblastic lymphoma; CR, complete remission; MRD, minimal residual disease; NHL-BFM-95, non-Hodgkin lymphoma Berlin--Frankfurt--Münster-95; HyperCVAD/MA, hyperfractionated cyclophosphamide, vincristine, adriamycin, dexamethasone/methotrexate, and cytarabine.

###### 

Prognostic factors associated with OS and PFS of T-LBL patients

  Prognostic factor                       Overall survival   Progression-free survival                                            
  --------------------------------------- ------------------ --------------------------- ---------- ---------- ------------------ ----------
  **Treatment**                                                                                                                   
   HyperCVAD/MA vs. modified NHL-BFM-95   0.006              1.66 (1.08-2.56)            0.021      0.004      2.32 (1.49-3.62)   \< 0.001
  **Age (yr)**                                                                                                                    
   ≥ 40 vs. \< 40                         0.429              \-                          \-         0.401      \-                 \-
  **Sex**                                                                                                                         
   Male vs. Female                        0.854              \-                          \-         0.493      \-                 \-
  **ECOG**                                                                                                                        
   \> 2 vs. ≤ 2                           0.038              2.37 (1.38-4.07)            0.002      0.040      2.16 (1.25-3.73)   0.006
  **WBC count at diagnose**                                                                                                       
   Abnormal vs. Normal                    0.760              \-                          \-         0.527      \-                 \-
  **Stage**                                                                                                                       
   Ⅰ/Ⅱ vs. Ⅲ/Ⅳ                            0.762              \-                          \-         0.503      \-                 \-
  **B symptom**                                                                                                                   
   Yes vs. No                             0.505              \-                          \-         0.143      \-                 \-
  **LDH elevated**                                                                                                                
   Yes vs. No                             0.105              \-                          \-         0.304      \-                 \-
  **Bone marrow invasion**                                                                                                        
   Yes vs. No                             0.002              2.71 (1.68-4.38)            \< 0.001   0.028      2.06 (1.27-3.32)   0.003
  **IPI**                                                                                                                         
   Low risk vs. High risk                 \< 0.001           \-                          \-         \< 0.001   \-                 \-

OS, overall survival; PFS, progression-free survival; T-LBL, T-lymphoblastic lymphoma; HR, hazard ratio; CI, confidence interval; NHL-BFM-95, non-Hodgkin lymphoma Berlin--Frankfurt--Münster-95; HyperCVAD/MA, hyper fractionated cyclophosphamide, vincristine, adriamycin, dexamethasone/methotrexate, and cytarabine; ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell; LDH, lactate dehydrogenase; IPI, international prognostic index.

###### 

Univariate analysis of prognostic factors for B lymphoblastic lymphoma patients

  Prognostic factor               5-Year OS   5-Year PFS          
  ------------------------------- ----------- ------------ ------ ----------
  **Treatment**                                                   
   Modified NHL-BFM-95            61.5        0.329        57.5   0.510
   HyperCVAD/MA                   49.8                     47.4   
  **Age (yr)**                                                    
   ≥ 40                           55.4        0.997        43.3   0.919
   \< 40                          60.3                     57.7   
  **Sex**                                                         
   Male                           50.9        0.546        49.2   0.721
   Female                         55.8                     48.6   
  **ECOG**                                                        
   ≤ 2                            58.6        0.429        49.1   0.533
   \> 2                           \-                       \-     
  **WBC count at diagnose**                                       
   Normal                         59.7        0.596        53.9   0.687
   Abnormal                       50.2                     46.4   
  **Stage at diagnosis**                                          
   Ⅰ/Ⅱ                            61.4        0.651        54.5   0.585
   Ⅲ/Ⅳ                            56.7                     47.5   
  **B symptom**                                                   
   Yes                            58.3        0.725        54.0   0.599
   No                             57.0                     42.6   
  **LDH elevated at diagnosis**                                   
   Yes                            33.6        \< 0.001     24.3   \< 0.001
   No                             94.7                     89.5   
  **Bone marrow invasion**                                        
   Yes                            41.9        0.151        \-     0.154
   No                             61.8                     50.7   
  **IPI**                                                         
   Low risk                       66.1        0.003        64.9   0.016
   High risk                      41.3                     37.5   

OS, overall survival; PFS, progression-free survival; NHL-BFM-95, non-Hodgkin lymphoma Berlin--Frankfurt--Münster-95; ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell; LDH, lactate dehydrogenase; IPI, international prognostic index.

###### 

Comparison of characteristics of modified NHL-BFM-95 and HyperCVAD with CALGB 10403

  Parameter                                  Modified NHL-BFM-95   HyperCVAD/MA   CALGB 10403
  ------------------------------------------ --------------------- -------------- -----------------------------------------------------
  **No.**                                    136                   71             295
  **Median age (yr)**                        28                    32             24
  **Age (%)**                                                                     
   \< 40                                     80.1                  64.8           100
   ≥ 40                                      19.9                  35.2           0
  **ECOG**                                                                        
   ≤ 2                                       77.9                  80.3           100
   \> 2                                      22.1                  19.7           0
  **Organ dysfunction allowed**              No                    No             No
  **Ph-positive LBL (%)**                    0                     0              31.3
  **T-cell LBL (%)**                         78.7                  70.4           24.1
  **CR after induction (%)**                 77.9                  66.2           89.0
  **MRD negative after consolidation (%)**   69.1                  60.1           44.0^[a)](#tfn3-crt-2019-542){ref-type="table-fn"}^
  **3-Year OS (%)**                          58.9                  38.8           73.0
  **3-Year PFS (%)**                         52.0                  34.7           EFS 59.0

NHL-BFM-95, non-Hodgkin lymphoma Berlin--Frankfurt--Münster-95; HyperCVAD/MA, hyperfractionated cyclophosphamide, vincristine, adriamycin, dexamethasone/methotrexate, and cytarabine; ECOG, Eastern Cooperative Oncology Group; LBL, lymphoblastic lymphoma; CR, complete remission; MRD, minimal residual disease; OS, overall survival; PFS, progression-free survival.

Pretreatment samples for Ph chromosome were available in 131 of the 223 B-cell patients in the study of CALGB 10403.

[^1]: Chun Li, Zhi-Jun Wuxiao, and Xiaoqin Chen contributed equally to this work.
